Keyphrases
Adult Patients
100%
Aggressive Disease
66%
Aggressive Phenotype
66%
Anti-glycan Antibodies
33%
Anti-Saccharomyces Cerevisiae Antibodies
33%
Antifibrotic
33%
Antineutrophil Cytoplasmic Antibody
66%
Biologic Therapy
66%
Carbohydrates
100%
CARD15
33%
CBir1
33%
Clinical Characteristics
33%
Clinical Features
33%
Clinical Practice
33%
Clinical Predictors
33%
Close Follow-up
33%
Crohn's Disease
100%
Demographic Predictors
33%
Disease Behavior
100%
Disease Course
66%
Disease Phenotype
100%
Disease Prognosis
33%
Disease Progression
33%
Early Identification
33%
Fibrostenosis
33%
Fibrostenotic
66%
Fibrostenotic Disease
66%
Fistula
33%
Fistula Formation
100%
Flagellin
33%
Genetic Markers
33%
Genetic Polymorphism
33%
Healing
33%
Hospitalization
33%
Immunomodulatory Therapy
66%
Inflammatory Bowel Disease
33%
Intestinal mucosa
33%
Mucosal Disease
33%
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
33%
Outer Membrane Porin
33%
Penetrating Disease
33%
Preventive Effect
33%
Primary Prevention
33%
Serum Biomarkers
66%
Stricture Formation
100%
Surgical Intervention
33%
Therapeutic Approaches
33%
Therapeutic Decision-making
33%
Therapeutic Strategies
33%
Toll-like Receptor 4 (TLR4)
33%
Biochemistry, Genetics and Molecular Biology
Anti-Neutrophil Cytoplasmic Antibody
100%
Anti-Saccharomyces Cerevisiae Antibody
100%
Flagellin
100%
Genetic Marker
100%
Genetic Polymorphism
100%
Intestine Mucosa
100%
Outer Membrane
100%
Polysaccharide
100%
Porin
100%
TLR4
100%
Medicine and Dentistry
Biological Product
20%
Biological Therapy
20%
Clinical Feature
20%
Clinical Predictor
20%
Crohn's Disease
60%
Disease Course
40%
Disease Exacerbation
20%
Diseases
100%
Fistula
100%
Flagellin
20%
Genetic Marker
20%
Genetic Polymorphism
20%
Glycan
20%
Immunomodulating Agent
40%
Inflammatory Bowel Disease
20%
Intestine Mucosa
20%
Mucosal Disease
20%
Neutrophil Cytoplasmic Antibody
40%
Outer Membrane
20%
Porin
20%
Primary Prevention
20%
Stricture
100%
Toll Like Receptor 4
20%
Immunology and Microbiology
Anti-Saccharomyces Cerevisiae Antibody
33%
Biological Product
33%
Crohn's Disease
100%
Flagellin
33%
Genetic Marker
33%
Genetic Polymorphism
33%
Glycan
33%
Immunomodulating Drugs
66%
Inflammatory Bowel Disease
33%
Intestine Mucosa
33%
Neutrophil Cytoplasmic Antibody
66%
Outer Membrane
33%
Porin
33%
TLR4
33%
Pharmacology, Toxicology and Pharmaceutical Science
Biological Product
20%
Clinical Feature
20%
Crohn's Disease
60%
Disease Course
40%
Disease Exacerbation
20%
Diseases
100%
Fistula
100%
Flagellin
20%
Glycan
20%
Immunomodulating Agent
40%
Inflammatory Bowel Disease
20%
Mucosal Disease
20%
Neutrophil Cytoplasmic Antibody
40%
Porin
20%
Saccharomyces cerevisiae
20%
Toll Like Receptor 4
20%